Management of High-Risk Retinoblastoma
- 819 Downloads
Invasion to the choroid, the sclera, and the optic nerve all constitute risk factors for extraocular relapse detected in enucleated eyes with retinoblastoma. Specifically, different degrees of invasion to these structures are associated with different risk and adjuvant therapy is tailored according to their presence. The relapse risk of children with isolated choroidal invasion is lower than 6 %, even in the higher risk subgroups with massive invasion and up to two thirds of those who relapse may be retrieved with intensive therapy. Hence, some groups use adjuvant therapy to further reduce the rate of extraocular relapse, while others do not give any treatment after enucleation. Most groups use adjuvant chemotherapy for children with postlaminar optic nerve invasion, but those with minor degrees of invasion may not need it. Since the relapse rate of these patients is low, the decision to use adjuvant therapy should be balanced in each setting with the possibility of fatal toxicities associated to chemotherapy.
Most groups use adjuvant therapy for those with scleral invasion and those with tumor at the resection margin of the optic nerve and more intensive regimens or orbital radiotherapy are recommended. Relapse in the central nervous system is the most common site for extraocular relapse in children receiving adjuvant therapy and it may become a sanctuary site when lower doses or drugs with low penetration to the cerebrospinal fluid are used. Molecular studies to determine the kinetics of minimal disease dissemination may provide more information.
KeywordsRetinoblastoma Optic nerve Choroid Scleral Pathology Chemotherapy Metastasis
Compliance with Ethical Requirements
Guillermo L. Chantada and Maria T.G. de Davila declare that they have no conflict of interest.
No human or animal studies were carried out by the authors for this article.
- Aerts I, Sastre-Garau X, Savignoni A, Lumbroso-Le Rouic L, Thebaud-Leculee E, Frappaz D, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31(11):1458–63. doi: 10.1200/JCO.2012.42.3962.CrossRefPubMedGoogle Scholar
- Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, Soares FA, Arias VA, Novaes PE, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29(10):700–4. doi: 10.1097/MPH.0b013e31814fb7ea.CrossRefPubMedGoogle Scholar
- Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer. 2009;100(10):1627–37. doi: 10.1038/sj.bjc.6605029.CrossRefPubMedCentralPubMedGoogle Scholar
- Biojone E, Queiroz Rde P, Valera ET, Odashima NS, Takayanagui OM, Viana MB, et al. Minimal residual disease in cerebrospinal fluid at diagnosis: a more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(1):89–95. doi: 10.3109/10428194.2011.606939.CrossRefPubMedGoogle Scholar
- Chantada GL, Gonzalez A, Fandino A, de Davila MT, Demirdjian G, Scopinaro M, et al. Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma. J Pediatr Hematol Oncol. 2009a;31(5):325–9. doi: 10.1097/MPH.0b013e3181923cc5.CrossRefPubMedGoogle Scholar
- Friedman DN, Sklar CA, Oeffinger KC, Kernan NA, Khakoo Y, Marr BP, et al. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr Blood Cancer. 2013;60(4):694–9. doi: 10.1002/pbc.24280.CrossRefPubMedGoogle Scholar
- Laurent VE, Sampor C, Solernou V, Rossi J, Gabri M, Eandi-Eberle S, et al. Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. Eur J Cancer. 2013;49(13):2892–9. doi: 10.1016/j.ejca.2013.04.021.CrossRefPubMedGoogle Scholar
- Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41–53, viii. doi:10.1016/j.ohc.2004.11.003.Google Scholar
- Potter SL, Berg S, Ingle AM, Krailo M, Adamson PC, Blaney SM. Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children’s Oncology Group trial (P9962). Pediatr Blood Cancer. 2012;58(3):362–5. doi: 10.1002/pbc.23317.CrossRefPubMedCentralPubMedGoogle Scholar
- Sastre X, Chantada GL, Doz F, Wilson MW, de Davila MT, Rodriguez-Galindo C, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133(8):1199–202. doi: 10.1043/1543-2165-133.8.1199.PubMedGoogle Scholar
- Torbidoni AV, Laurent VE, Sampor C, Ottaviani D, Vazquez V, Gabri MR, Rossi J, de Dávila MT, Alonso C, Alonso DF, Chantada GL. Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma. JAMA Ophthalmol. 2015 2015. doi: 10.1001/jamaophthalmol.2015.0900 [Epub ahead of print].